{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:19:20Z","timestamp":1787822360536,"version":"build-2784847793"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.gene.2026.150314","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:01:31Z","timestamp":1783954891000},"page":"150314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting DNA topoisomerase II in Cancer: mechanism of inhibition, clinical utility, and future directions"],"prefix":"10.1016","volume":"1010","author":[{"family":"Radhika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Vashist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2026.150314_b0005","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1021\/cr200325f","article-title":"Contemporary challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy","volume":"112","author":"Bailly","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.gene.2026.150314_b0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.03.034","article-title":"A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade","volume":"171","author":"Liang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150314_b0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/cm.10037","article-title":"Micro-patterning tractional forces in living cells","volume":"52","author":"Wang","year":"2002","journal-title":"Cell Motil. Cytoskelet."},{"key":"10.1016\/j.gene.2026.150314_b0035","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1021\/acs.jmedchem.3c02115","article-title":"Unleashing the potential of Camptothecin: Exploring innovative strategies for Structural Modification and Therapeutic Advancements","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150314_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s44178-025-00208-x","article-title":"Combination of approved chemotherapeutics and natural products for topoisomerase II targeting: efficacy and safety in cancer therapy","volume":"4","author":"El-Far","year":"2025","journal-title":"Holist Integ Oncol"},{"issue":"1","key":"10.1016\/j.gene.2026.150314_b0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.virol.2007.02.037","article-title":"Variola virus topoisomerase: DNA cleavage specificity and distribution of sites in Poxvirus genomes","volume":"365","author":"Minkah","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.gene.2026.150314_b0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.gene.2026.150314_b0055","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.3390\/ijms24043986","article-title":"What's on the Other Side of the Gate: a Structural Perspective on DNA Gate opening of Type IA and IIA DNA Topoisomerases","volume":"24","author":"Vidmar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2026.150314_b0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.gene.2026.150314_b0065","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.3390\/molecules25204769","article-title":"Mechanism of Type IA Topoisomerases","volume":"25","author":"Dasgupta","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.gene.2026.150314_b0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S003358350800468X","article-title":"DNA topoisomerases: harnessing and constraining energy to govern chromosome topology","volume":"41","author":"Schoeffler","year":"2008","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.gene.2026.150314_b0075","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1365-2958.2004.04047.x","article-title":"Untangling intracellular DNA topology","volume":"52","author":"Espeli","year":"2004","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.gene.2026.150314_b0080","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.gene.2026.150314_b0085","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"6","author":"Wang","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.gene.2026.150314_b0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BCJ20160583","article-title":"Topoisomerases as Anticancer Targets","volume":"475","author":"Delgado","year":"2018","journal-title":"Biochem. J"},{"issue":"22","key":"10.1016\/j.gene.2026.150314_b0095","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.gene.2026.150314_b0100","doi-asserted-by":"crossref","first-page":"9766","DOI":"10.1073\/pnas.171579898","article-title":"Type I topoisomerase activity is required for proper chromosomal segregation in Escherichia coli","volume":"98","author":"Zhu","year":"2001","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.gene.2026.150314_b0105","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual inhibitors of human DNA topoisomerase II and Other Cancer-Related Targets","volume":"63","author":"Skok","year":"2020","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.gene.2026.150314_b0110","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.3390\/ijms241311199","article-title":"Telling your right Hand from your Left: the Effects of DNA Supercoil Handedness on the Actions of Type II Topoisomerases","volume":"24","author":"Jian","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.gene.2026.150314_b0115","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s10620-017-4718-4","article-title":"Overexpression of topoisomerase 2-alpha confers a poor prognosis in pancreatic adenocarcinoma identified by co-expression analysis","volume":"62","author":"Zhou","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.gene.2026.150314_b0120","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1080\/21655979.2021.2023985","article-title":"DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating \u03b2-catenin","volume":"13","author":"Liu","year":"2022","journal-title":"Bioengineered"},{"issue":"11","key":"10.1016\/j.gene.2026.150314_b0125","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1093\/nar\/gkab270","article-title":"What makes a type IIA topoisomerase a gyrase or a Topo IV?","volume":"49","author":"Hirsch","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.gene.2026.150314_b0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2018.04.059","article-title":"New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV","volume":"152","author":"Badshah","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150314_b0135","doi-asserted-by":"crossref","first-page":"11338","DOI":"10.1371\/journal.pone.0011338","article-title":"Structural basis of gate-DNA breakage and resealing by type II topoisomerases","volume":"5","author":"Laponogov","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2026.150314_b0140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nsmb.2388","article-title":"Structure of a topoisomerase II\u2013DNA\u2013nucleotide complex reveals a new control mechanism for ATPase activity","volume":"19","author":"Schmidt","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.gene.2026.150314_b0145","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nature06396","article-title":"Structural basis for gate-DNA recognition and bending by type IIA topoisomerases","volume":"450","author":"Dong","year":"2007","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.gene.2026.150314_b0150","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/bjc.1997.227","article-title":"The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues","volume":"75","author":"Turley","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.gene.2026.150314_b0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0163-7258(03)00058-5","article-title":"Catalytic topoisomerase II inhibitors in cancer therapy","volume":"99","author":"Larsen","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.gene.2026.150314_b0160","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.gene.2026.150314_b0165","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202209125","article-title":"Cell Cycle responses to Topoisomerase II Inhibition: Molecular Mechanisms and Clinical Implications","volume":"222","author":"Soliman","year":"2023","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.gene.2026.150314_b0170","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/md20110674","article-title":"Marine-Derived Compounds Targeting Topoisomerase II in Cancer Cells: a Review","volume":"20","author":"Greco","year":"2022","journal-title":"Mar. Drugs"},{"issue":"21","key":"10.1016\/j.gene.2026.150314_b0175","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/acs.biochem.1c00240","article-title":"Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors","volume":"60","author":"Vann","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.gene.2026.150314_b0180","doi-asserted-by":"crossref","unstructured":"G. Capranico, S. Tinelli, C.A. Austin, M.L. Fisher, F. Zunino, Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development, Biochim Biophys. Acta, 1132 (1) (1992) 43\u201348, https:\/\/doi. org\/10.1016\/0167-4781(92)90050-a.","DOI":"10.1016\/0167-4781(92)90050-A"},{"key":"10.1016\/j.gene.2026.150314_b0185","first-page":"221","article-title":"Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice","volume":"1470","author":"Fortune","year":"2000","journal-title":"BBA"},{"key":"10.1016\/j.gene.2026.150314_b0190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.gene.2026.150314_b0195","first-page":"1772","article-title":"Topoisomerase II Poisons and Catalytic Inhibitors: Mechanisms of Action and Cellular responses","volume":"14","author":"Nitiss","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.gene.2026.150314_b0200","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.gene.2026.150314_b0205","first-page":"357","article-title":"Etoposide, topoisomerase II and cancer","volume":"12","author":"Baldwin","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.gene.2026.150314_b0210","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of Eukaryotic Topoisomerases in Transcription, Replication and Genomic Stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.gene.2026.150314_b0215","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202209125","article-title":"Cell cycle responses to Topoisomerase II inhibition: Molecular mechanisms and clinical implications","volume":"222","author":"Soliman","year":"2023","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.gene.2026.150314_b0220","doi-asserted-by":"crossref","unstructured":"T.J. Nicholls, C.A. Nadalutti, E. Motori, et al., Topoisomerase 3\u03b1 Is Required for Decatenation and Segregation of Human mtDNA, Mol. Cell 69 (1) (2018) 9\u201323. e6, Doi: 10.1016\/j.molcel.2017.11.033.","DOI":"10.1016\/j.molcel.2017.11.033"},{"issue":"12","key":"10.1016\/j.gene.2026.150314_b0225","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.3390\/curroncol31120594","article-title":"Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications","volume":"31","author":"Borella","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0230","doi-asserted-by":"crossref","first-page":"11014","DOI":"10.1073\/pnas.0704002104","article-title":"Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies","volume":"104","author":"Azarova","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.gene.2026.150314_b0235","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2006.02.045","article-title":"Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer","volume":"65","author":"O\u2019Connor","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.gene.2026.150314_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2025.169309","article-title":"Post-Translational modifications Orchestrate Repair of Trapped Topoisomerase-Induced DNA Breaks via TDP1 and TDP2","volume":"438","author":"Das","year":"2026","journal-title":"J. Mol. Biol."},{"issue":"2017","key":"10.1016\/j.gene.2026.150314_b0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"ELN recommendations","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.gene.2026.150314_b0250","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150314_b0255","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12943-025-02444-1","article-title":"Safe delivery of a highly toxic anthracycline derivative through liposomal nanoformulation achieves complete cancer regression","volume":"24","author":"F\u00fcredi","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.gene.2026.150314_b0260","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2515176","article-title":"Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin","volume":"14","author":"Cerrato","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.gene.2026.150314_b0265","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Cardiac toxicity secondary to anthracycline therapy in patients with breast cancer","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.gene.2026.150314_b0270","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1134\/S0006297923070040","article-title":"Mechanisms of Secondary Leukemia Development Caused by Treatment with DNA Topoisomerase Inhibitors","volume":"88","author":"Lomov","year":"2023","journal-title":"Biochem. Mosc."},{"issue":"2","key":"10.1016\/j.gene.2026.150314_b0275","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3892\/mmr.2024.13415","article-title":"Advances in Research on Malignant Tumors and Targeted Agents for TOP2A (Review)","volume":"31","author":"Zhou","year":"2025","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.gene.2026.150314_b0280","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood.2024024788","article-title":"How I treat older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"145","author":"Wallace","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.gene.2026.150314_b0285","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"21","author":"Sen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0290","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (IMpower133)","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150314_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1489977","article-title":"Biomarkers for immunotherapy resistance in non-small cell lung cancer","volume":"14","author":"Rother","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0300","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40959-025-00332-7","article-title":"Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis","volume":"11","author":"Liu","year":"2025","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.gene.2026.150314_b0305","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.annonc.2025.08.002","article-title":"Impact of anthracyclines in genomic high-risk, node-negative, HR-positive\/HER2-negative breast cancer","volume":"36","author":"Chen","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0310","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment for node-positive primary breast cancer","volume":"21","author":"Citron","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0315","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.gene.2026.150314_b0320","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/oncolo\/oyae194","article-title":"Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study","volume":"30","author":"Zhang","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.gene.2026.150314_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2025.101727","article-title":"Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies","volume":"58","author":"Levytska","year":"2025","journal-title":"Gynecologic Oncology Reports"},{"key":"10.1016\/j.gene.2026.150314_b0330","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase III trial of pegylated liposomal doxorubicin in ovarian cancer","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.gene.2026.150314_b0335","article-title":"Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer","volume":"7","author":"Newhouse","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.gene.2026.150314_b0340","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.3390\/curroncol31120594","article-title":"Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications","volume":"31","author":"Borella","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40364-025-00797-9","article-title":"Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer","volume":"13","author":"Wang","year":"2025","journal-title":"Biomark Res."},{"key":"10.1016\/j.gene.2026.150314_b0350","doi-asserted-by":"crossref","first-page":"10241","DOI":"10.1038\/s41467-025-65005-6","article-title":"Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes","volume":"16","author":"Uusk\u00fcla-Reimand","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gene.2026.150314_b0355","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cancergen.2024.10.005","article-title":"Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies","volume":"289","author":"Liu","year":"2024","journal-title":"Cancer Genet."},{"key":"10.1016\/j.gene.2026.150314_b0360","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.gene.2026.150314_b0365","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1335196","article-title":"How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature","volume":"14","author":"Arcieri","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0380","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41392-024-01794-4","article-title":"Anti-lymphangiogenesis for boosting drug accumulation in tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.gene.2026.150314_b0385","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.gene.2026.150314_b0390","first-page":"749","article-title":"A Mandal, Z. M. Delwar Drug delivery Nanocarriers for the Treatment of Cancer and their Role in Overcoming Multidrug Resistance","volume":"15","author":"Khan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150314_b0395","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1080\/14756366.2020.1821676","article-title":"DNA topoisomerases as molecular targets for anticancer drugs","volume":"35","author":"Buzun","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.gene.2026.150314_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107457","article-title":"Flavonoids and their derivatives as DNA topoisomerase inhibitors with anti-cancer activity in various cell models: Exploring a novel mode of action","volume":"209","author":"Sitarek","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.gene.2026.150314_b0405","doi-asserted-by":"crossref","unstructured":"A. V\u0301avrov\u0301a, T. \u02c7Sim\u016fnek, DNA topoisomerase II\u03b2: a player in regulation of gene expression and cell differentiation, Int J. Biochem Cell Biol. 44 (6) (2012) 834\u2013837, Doi: 10.1016\/j.biocel.2012.03.005.","DOI":"10.1016\/j.biocel.2012.03.005"},{"issue":"8","key":"10.1016\/j.gene.2026.150314_b0410","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/JB.188.8.3002-3011.2006","article-title":"Differential and dynamic localization of topoisomerases in Bacillus subtilis","volume":"188","author":"Tadesse","year":"2006","journal-title":"J. Bacteriol."},{"issue":"2","key":"10.1016\/j.gene.2026.150314_b0415","first-page":"239","article-title":"Analysis of foetal expression sites of human type II DNA topoisomerase alpha and beta mRNAs by in situ hybridisation","volume":"1307","author":"Zandvliet","year":"1996","journal-title":"BBA"},{"issue":"5","key":"10.1016\/j.gene.2026.150314_b0420","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCRESAHA.108.183905","article-title":"Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells","volume":"104","author":"Eisenreich","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.gene.2026.150314_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103866","article-title":"DNA topoisomerase II\u00df inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models","volume":"152","author":"Camarillo","year":"2025","journal-title":"DNA Repair"},{"key":"10.1016\/j.gene.2026.150314_b0430","series-title":"Chapter 2 - Combination therapy against multidrug resistance","first-page":"39","author":"Marimani","year":"2020"},{"key":"10.1016\/j.gene.2026.150314_b0435","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the Role of ABC Transporters in Multidrug-Resistant Cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.gene.2026.150314_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103662","article-title":"Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic","volume":"28","author":"Priya","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.gene.2026.150314_b0445","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4155\/ppa-2019-0020","article-title":"Liposome-based Drug delivery of Various Anticancer Agents of Synthetic and Natural Product Origin: a Patent Overview","volume":"9","author":"Akhtar","year":"2020","journal-title":"Pharm. Pat. Anal."},{"issue":"3","key":"10.1016\/j.gene.2026.150314_b0450","first-page":"163","article-title":"Drug delivery research for the future: Expanding the nano horizons and beyond","volume":"22","author":"Mitragotri","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.gene.2026.150314_b0455","article-title":"Recent advances in Multifunctional Topoisomerase II Inhibitors for Cancer Therapy","volume":"252","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.gene.2026.150314_b0460","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/md20110674","article-title":"Marine-Derived Compounds Targeting Topoisomerase II in Cancer Cells: a Review","volume":"20","author":"Greco","year":"2022","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.gene.2026.150314_b0465","article-title":"Recent Progress in Dual-Target Anticancer Agents based on Topoisomerase II Inhibition","volume":"237","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.gene.2026.150314_b0470","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.gene.2026.150314_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104551","article-title":"Topoisomerase inhibitors: pharmacology and emerging nanoscale delivery systems","volume":"151","author":"Dehshahri","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.gene.2026.150314_b0480","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/ijms24032532","article-title":"A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents","volume":"24","author":"Okoro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.gene.2026.150314_b0485","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.gene.2026.150314_b0490","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3390\/cells10113138","article-title":"A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and less Cardiotoxicity","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.gene.2026.150314_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106565","article-title":"Upgrade of chrysomycin a as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression","volume":"187","author":"Zhang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.gene.2026.150314_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105543","article-title":"Structural optimizations and bioevaluation of N-substituted acridone derivatives as strong topoisomerase II inhibitors","volume":"119","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.gene.2026.150314_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116360","article-title":"Quinoxaline derivatives: recent discoveries and development strategies towards anticancer agents","volume":"271","author":"Montero","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.gene.2026.150314_b0510","doi-asserted-by":"crossref","first-page":"23690","DOI":"10.1002\/jbt.23690","article-title":"N-allyl quinoxaline derivative exhibited potent and selective cytotoxicity through EGFR\/VEGFR-mediated apoptosis: In vitro and in vivo studies","volume":"38","author":"Nafie","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"12","key":"10.1016\/j.gene.2026.150314_b0515","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2174\/0113895575370547250526062144","article-title":"Topoisomerase II Inhibition in Cancer: a Focus on Metal Complexes","volume":"25","author":"Akinyemi","year":"2025","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.gene.2026.150314_b0520","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41569-025-01126-1","article-title":"Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment","volume":"22","author":"Fabiani","year":"2025","journal-title":"Nat Rev Cardio."},{"key":"10.1016\/j.gene.2026.150314_b0525","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40364-024-00638-1","article-title":"Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics","volume":"12","author":"Feng","year":"2024","journal-title":"Biomark Res."},{"key":"10.1016\/j.gene.2026.150314_b0530","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijbiomac.2022.12.013","article-title":"Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeutics","volume":"226","author":"Singh","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"239","key":"10.1016\/j.gene.2026.150314_b0535","article-title":"A comprehensive review on acridone-based derivatives as future anti-cancer agents and their structure\u2013activity relationships","volume":"2022","author":"Yadav","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150314_b0540","doi-asserted-by":"crossref","first-page":"33080","DOI":"10.1039\/D3RA06189B","article-title":"Novel 2-substituted-quinoxaline analogs with potential antiproliferative activity against breast cancer: insights into cell cycle arrest, topoisomerase II, and EGFR activity","volume":"13","author":"Salem","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.gene.2026.150314_b0545","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/s41598-025-85929-9","article-title":"Multi-omics analysis reveals the panoramic picture of TOP2A in pan-cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.gene.2026.150314_b0550","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/cancers14040907","article-title":"PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's now, What's New, and What's coming?","volume":"14","author":"Marchetti","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.gene.2026.150314_b0555","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17425255.2022.2072727","article-title":"Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis","volume":"18","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.gene.2026.150314_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116807","article-title":"Identification of a novel 10-hydroxyevodiamine prodrug as a potent topoisomerase inhibitor with improved aqueous solubility for treatment of hepatocellular carcinoma","volume":"279","author":"Wei","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.gene.2026.150314_b0565","doi-asserted-by":"crossref","first-page":"13519","DOI":"10.3390\/ijms222413519","article-title":"An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: a Focus on DDR","volume":"22","author":"Mollica","year":"2021","journal-title":"MSI and AKT. Int J Mol Sci."},{"issue":"3","key":"10.1016\/j.gene.2026.150314_b0570","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers13030546","article-title":"Bone Targeting Agents in patients with Metastatic Prostate Cancer: State of the Art","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gene.2026.150314_b0575","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","article-title":"Synthetic lethal strategies for the development of cancer therapeutics","volume":"22","author":"Ngoi","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0580","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/ijms26020583","article-title":"Immunotherapy in Oncogene-Addicted NSCLC: evidence and Therapeutic Approaches","volume":"26","author":"Foffano","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2026.150314_b0585","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning Cold into Hot: Firing up the Tumor Microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.gene.2026.150314_b0590","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with Chemotherapy in the Era of Immune Checkpoint Inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150314_b0595","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2432726","article-title":"Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7thimmunorad conference","volume":"14","author":"Laurent","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.gene.2026.150314_b0600","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3390\/jcm14051735","article-title":"Precision Medicine in Rheumatology: the Role of Biomarkers in Diagnosis and Treatment Optimization","volume":"14","author":"Colina","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.gene.2026.150314_b0605","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s13530-024-00243-7","article-title":"A comprehensive review of cadmium-induced toxicity, signalling pathways, and potential mitigation strategies","volume":"17","author":"Vijiyakumar","year":"2025","journal-title":"Toxicol. Environ. Health Sci."},{"key":"10.1016\/j.gene.2026.150314_b0610","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/ph16101456","article-title":"Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents","volume":"16","author":"Yakkala","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"20","key":"10.1016\/j.gene.2026.150314_b0615","doi-asserted-by":"crossref","first-page":"11291","DOI":"10.1073\/pnas.1534874100","article-title":"Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription","volume":"100","author":"Da Fonseca","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.gene.2026.150314_b0620","doi-asserted-by":"crossref","DOI":"10.1186\/s41021-025-00326-y","article-title":"Cancer prevention: past challenges and future directions","volume":"47","author":"Seong","year":"2025","journal-title":"Genes and Environ"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111926003240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111926003240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:30:52Z","timestamp":1787819452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111926003240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":119,"alternative-id":["S0378111926003240"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2026.150314","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting DNA topoisomerase II in Cancer: mechanism of inhibition, clinical utility, and future directions","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2026.150314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150314"}}